These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16306730)

  • 1. Influence of sevoflurane on the metabolism and renal effects of compound A in rats.
    Kharasch ED; Schroeder JL; Sheffels P; Liggitt HD
    Anesthesiology; 2005 Dec; 103(6):1183-8. PubMed ID: 16306730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats.
    Sheffels P; Schroeder JL; Altuntas TG; Liggitt HD; Kharasch ED
    Chem Res Toxicol; 2004 Sep; 17(9):1177-89. PubMed ID: 15377151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of renal cysteine conjugate beta-lyase in the mechanism of compound A nephrotoxicity in rats.
    Kharasch ED; Thorning D; Garton K; Hankins DC; Kilty CG
    Anesthesiology; 1997 Jan; 86(1):160-71. PubMed ID: 9009951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the renal cysteine conjugate beta-lyase pathway in inhaled compound A nephrotoxicity in rats.
    Kharasch ED; Hoffman GM; Thorning D; Hankins DC; Kilty CG
    Anesthesiology; 1998 Jun; 88(6):1624-33. PubMed ID: 9637657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compound A uptake and metabolism to mercapturic acids and 3,3,3-trifluoro-2-fluoromethoxypropanoic acid during low-flow sevoflurane anesthesia: biomarkers for exposure, risk assessment, and interspecies comparison.
    Kharasch ED; Jubert C
    Anesthesiology; 1999 Nov; 91(5):1267-78. PubMed ID: 10551576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity.
    Kharasch ED; Frink EJ; Zager R; Bowdle TA; Artru A; Nogami WM
    Anesthesiology; 1997 Jun; 86(6):1238-53. PubMed ID: 9197292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative differences in the production and toxicity of CF2=BrCl versus CH2F-O-C(=CF2)(CF3) (compound A): the safety of halothane does not indicate the safety of sevoflurane.
    Eger EI; Ionescu P; Laster MJ; Gong D; Weiskopf RB; Kerschmann RL
    Anesth Analg; 1997 Nov; 85(5):1164-70. PubMed ID: 9356119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cysteine conjugate beta-lyase-dependent metabolism of compound A (2-[fluoromethoxy]-1,1,3,3,3-pentafluoro-1-propene) in human subjects anesthetized with sevoflurane and in rats given compound A.
    Iyer RA; Frink EJ; Ebert TJ; Anders MW
    Anesthesiology; 1998 Mar; 88(3):611-8. PubMed ID: 9523802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Compound A: toxicology and clinical relevance].
    Kharasch ED
    Anaesthesist; 1998 Nov; 47 Suppl 1():S7-10. PubMed ID: 9893874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiling of nephrotoxicity from the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether ("compound A") in rats.
    Kharasch ED; Schroeder JL; Bammler T; Beyer R; Srinouanprachanh S
    Toxicol Sci; 2006 Apr; 90(2):419-31. PubMed ID: 16384817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrotoxicity of the glutathione and cysteine S-conjugates of the sevoflurane degradation product 2-(fluoromethoxy)-1,1,3,3, 3-pentafluoro-1-propene (Compound A) in male Fischer 344 rats.
    Iyer RA; Baggs RB; Anders MW
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1544-51. PubMed ID: 9400032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrotoxicity of sevoflurane compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] in rats: evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate beta-lyase.
    Jin L; Baillie TA; Davis MR; Kharasch ED
    Biochem Biophys Res Commun; 1995 May; 210(2):498-506. PubMed ID: 7755627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunochemical evidence against the involvement of cysteine conjugate beta-lyase in compound A nephrotoxicity in rats.
    Njoku DB; Pohl LR; Sokoloski EA; Marchick MR; Borkowf CB; Martin JL
    Anesthesiology; 1999 Feb; 90(2):458-69. PubMed ID: 9952153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal toxicity with sevoflurane: a storm in a teacup?
    Gentz BA; Malan TP
    Drugs; 2001; 61(15):2155-62. PubMed ID: 11772127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhalation toxicity study of a haloalkene degradant of sevoflurane, Compound A (PIFE), in Sprague-Dawley rats.
    Keller KA; Callan C; Prokocimer P; Delgado-Herrera L; Friedman MB; Hoffman GM; Wooding WL; Cusick PK; Krasula RW
    Anesthesiology; 1995 Dec; 83(6):1220-32. PubMed ID: 8533915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-flow sevoflurane compared with low-flow isoflurane anesthesia in patients with stable renal insufficiency.
    Conzen PF; Kharasch ED; Czerner SF; Artru AA; Reichle FM; Michalowski P; Rooke GA; Weiss BM; Ebert TJ
    Anesthesiology; 2002 Sep; 97(3):578-84. PubMed ID: 12218523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line.
    Altuntas TG; Zager RA; Kharasch ED
    Toxicol Appl Pharmacol; 2003 Nov; 193(1):55-65. PubMed ID: 14613716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fate and toxicity of 2-(fluoromethoxy)-1,1,3,3,3-pentafluoro-1-propene (compound A)-derived mercapturates in male, Fischer 344 rats.
    Uttamsingh V; Iyer RA; Baggs RB; Anders MW
    Anesthesiology; 1998 Nov; 89(5):1174-83. PubMed ID: 9822006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism of compound A by renal cysteine-S-conjugate beta-lyase is not the mechanism of compound A-induced renal injury in the rat.
    Martin JL; Laster MJ; Kandel L; Kerschmann RL; Reed GF; Eger EI
    Anesth Analg; 1996 Apr; 82(4):770-4. PubMed ID: 8615496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biotransformation of L-cysteine S-conjugates and N-acetyl-L-cysteine S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human kidney in vitro: interindividual variability in N-acetylation, N-deacetylation, and beta-lyase-catalyzed metabolism.
    Gul Altuntas T; Kharasch ED
    Drug Metab Dispos; 2002 Feb; 30(2):148-54. PubMed ID: 11792683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.